Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) shares rose 1.5% on Tuesday . The company traded as high as $7.08 and last traded at $6.23. Approximately 16,598 shares changed hands during trading, an increase of 76% from the average daily volume of 9,431 shares. The stock had previously closed at $6.14. Adlai Nortye Stock […]
Adlai Nortye Ltd to Present Encouraging Data of the globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Adlai Nortye Ltd to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Adlai Nortye Ltd. announced that the first patient was dosed in the Phase II clinical trial known as ARTEMIS . This clinical study evaluates palupiprant , a small molecule prostaglandin E receptor 4 .
Adlai Nortye Ltd (NASDAQ:ANL) Short Interest Update defenseworld.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from defenseworld.net Daily Mail and Mail on Sunday newspapers.